BAY1902607 + Placebo
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clinical Trials, Phase I as Topic
Conditions
Clinical Trials, Phase I as Topic
Trial Timeline
Jul 18, 2017 → Jul 27, 2018
NCT ID
NCT03212586About BAY1902607 + Placebo
BAY1902607 + Placebo is a phase 1 stage product being developed by Bayer for Clinical Trials, Phase I as Topic. The current trial status is completed. This product is registered under clinical trial identifier NCT03212586. Target conditions include Clinical Trials, Phase I as Topic.
What happened to similar drugs?
1 of 4 similar drugs in Clinical Trials, Phase I as Topic were approved
Approved (1) Terminated (1) Active (3)
Hype Score Breakdown
Clinical
6
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03212586 | Phase 1 | Completed |
Competing Products
20 competing products in Clinical Trials, Phase I as Topic